KRYS Stock Analysis: Buy, Sell, or Hold?
KRYS - Krystal Biotech, Inc. Common Stock
$312.57
-28.55 (-8.37%)
▼
5d:
-11.16%
30d:
-16.66%
90d:
+17.49%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Get Alerted When KRYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KRYS is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KRYS is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$434.96
Based on 12.2% avg growth
INTRINSIC VALUE TODAY
$270.07
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KRYS is currently trading at $312.57, which is considered oversold relative to its 30-day fair value range of $338.78 to $373.17. The stock's valuation (Forward PE: 31.7) is in line with its historical norms (29.4). At these levels, the market is pricing in 2.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KRYS is in a strong uptrend. Immediate support is located at $297.02, while resistance sits at $369.00. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $384.43 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KRYS is in a strong uptrend. Immediate support is located at $297.02, while resistance sits at $369.00. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $384.43 (+23.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$338.78 -
$373.17
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding KRYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 23.0% below Wall St target ($384.43)
- NEUTRAL: Market pricing in 2.5% annual earnings growth - fairly valued
- WARNING: Recommendation downgraded due to -11.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$338.78 -
$373.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$297.02
Resistance Level
$369.00
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.66
Wall Street Target
$384.43
(+23.0%)
Revenue Growth (YoY)
31.9%
Earnings Growth (YoY)
52.5%
Profit Margin
53.9%
Valuation Premium vs History
+2.5% premium
PE vs Historical
31.7 vs 29.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.5%
(market-implied from PE analysis)
1-Year Target
$320.38
(+3%)
2-Year Target
$328.39
(+5%)
3-Year Target
$336.60
(+8%)
3-Yr Target (if PE normalizes)
(PE: 32→29)
PE COMPRESSION
$312.54
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.7, Growth: 20.3%)
$544.19
(+74%)
Base:
(SPY PE: 20.7, Growth: 20.3%)
$356.27
(+14%)
Bear:
(PE: 17.6, Growth: 20.3%)
$302.83
(-3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (32x PE) as earnings recover.
Trailing PE: 45.67 | Current EPS (TTM): $7.47
Bull Case
$495.86
(+59%)
Analyst growth 32.1%, PE expands to 50.2
Base Case
$450.79
(+44%)
Market implied 32.1%, PE stable at 45.7
Bear Case
$231.96
(-26%)
Severe decline -20.0%, PE contracts to 38.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 3:24 AM ET
Data refreshes hourly during market hours. Next update: 4:24 AM
Data refreshes hourly during market hours. Next update: 4:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KRYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Suma Krishnan
SELL
25000 shares
2026-03-04
Kathryn Romano
SELL
750 shares
2026-03-02
Daniel Janney
SELL
11803 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
Advanced KRYS Option Strategies
Professional options setups generated by AI based on today's KRYS price and gamma walls.
